• LAST PRICE
    2.8800
  • TODAY'S CHANGE (%)
    Trending Up0.5000 (21.0084%)
  • Bid / Lots
    2.6100/ 1
  • Ask / Lots
    3.1000/ 10
  • Open / Previous Close
    2.3780 / 2.3800
  • Day Range
    Low 2.3780
    High 2.9000
  • 52 Week Range
    Low 1.8100
    High 3.5700
  • Volume
    57,874
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 2.38
TimeVolumeIPHA
10:17 ET5002.378
11:49 ET3972.39
12:07 ET1152.39
12:12 ET3002.4
12:16 ET4002.4
12:30 ET4002.39
12:43 ET6032.4
01:08 ET13802.49
01:17 ET4002.5
01:26 ET4002.5
01:30 ET10522.585
02:00 ET47022.6899
02:08 ET8742.7
02:45 ET32002.75
03:03 ET1002.7
03:12 ET6002.64
03:25 ET31672.9
03:30 ET7002.725
03:41 ET3552.8
03:43 ET1432.8
03:45 ET2282.8
03:52 ET59982.82
03:56 ET55692.88
03:57 ET2002.84
03:59 ET41472.88
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIPHA
Innate Pharma SA
191.3M
-31.7x
---
United StatesRPTX
Repare Therapeutics Inc
198.7M
-2.1x
---
United StatesCDXS
Codexis Inc
245.4M
-3.1x
---
United StatesALIM
Alimera Sciences Inc
204.2M
-1.8x
---
United StatesPSTX
Poseida Therapeutics Inc
307.8M
-2.3x
---
United StatesPLX
Protalix Biotherapeutics Inc
92.0M
18.2x
---
As of 2024-03-29

Company Information

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.

Contact Information

Headquarters
117 avenue de Luminy, Bp 30191MARSEILLE, France 13009
Phone
---
Fax
---

Executives

Independent Chairwoman of the Supervisory Board
Irina Staatz-Granzer
Chairman of the Executive Board, Interim Chief Executive Officer
Herve Brailly
Chief Financial Officer, Member of the Executive Committee
Frederic Lombard
Chief Operating Officer, Executive Vice President, Member of the Executive Board
Yannis Morel
Executive Vice President, Chief Medical Officer, Member of the Executive Committee
Joyson Karakunnel

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$191.3M
Revenue (TTM)
$56.0M
Shares Outstanding
80.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.27
EPS
$-0.09
Book Value
$0.69
P/E Ratio
-31.7x
Price/Sales (TTM)
3.4
Price/Cash Flow (TTM)
---
Operating Margin
-24.41%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.